Mesothelioma Vaccine to Enter Second Phase of Testing
Aduro Bio Tech, makers of a new cancer vaccine, are enrolling the first round of mesothelioma patients in a study that will pair their drug with chemotherapy according to Surviving Mesothelioma.
Raleigh, NC (PRWEB) October 23, 2012
Manufactured by Aduro Bio Tech, a new drug, known as CRS-207, is being paired with chemotherapy treatments in order to hopefully combat mesothelioma.
Each year, approximately 2,000 new cases of mesothelioma are diagnosed within the United States alone. Part of what makes this rare form of cancer so dangerous is its latency period. It can take from 20-50 years for a person to develop mesothelioma after exposure to asbestos. Asbestos is the cause of mesothelioma.
Research scientists at Aduro Bio Tech are hopeful that the drug will provide a form of immunotherapy treatment for mesothelioma patients.
How does CRS-207 work?
CRS-207 is based on a less potent version of Listeria, a type of bacteria. It is then modified by scientists to illicit an immune response to cells that produce mesothelin, a tumor-associated antigen produced by a variety of cancer cells, including mesothelioma cells.
Recent trials with mesothelioma patients who were administered CRS-207 were found to have slightly longer life expectancies than those who didn’t receive the treatment, leading researchers to now conduct a second phase of testing.
Testing is currently being conducted at the National Cancer Institute, located in Bethesda, Maryland and is set to conclude in December 2013. For more information see “Mesothelioma Vaccine Enters Phase 2 Testing” available by clicking here.
About Surviving Mesothelioma:
Surviving Mesothelioma is a website dedicated to providing information, news, and resources for mesothelioma patients and their loved ones. Supported by the Cancer Monthly organization, Surviving Mesothelioma reports on the latest news regarding mesothelioma treatments, information about finding mesothelioma doctors, treatment results, and books and testimonials from mesothelioma patients and survivors.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/10/prweb10023204.htm